Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...

Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss ... pill led to an average weight loss of 15% over 68 weeks, a similar result as seen in trials of Wegovy.

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Nearly 4.4 million adult New Yorkers, or 30%, has obesity, but access to weight-loss medications varies based on a variety of ...